Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cannabis oil stop severe itching? new trial aims to find out

NCT ID NCT06435299

Symptom relief Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a cannabis oil containing a balanced mix of THC and CBD can safely reduce severe chronic itching. About 218 adults with severe itch (score 7 or higher on a 0-10 scale) that hasn't improved with other treatments will take either the cannabis oil or a placebo twice daily for 6 weeks. The main goal is to see if at least 30% more people in the cannabis group report a meaningful reduction in itch compared to the placebo group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cannabis oil (THC 25:CBD 25)
What this could lead to
If it works, this could offer a new treatment option for people with severe chronic itching that hasn't responded to other therapies.
What could go wrong
This is an early phase 2 trial, so it may not show a clear benefit. Side effects from THC, like dizziness or drowsiness, are possible, and the oil may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Severe pruritus, defined by a mean WI-NRS score ≥7/10 (evaluated on one week before inclusion, regardless of the cause of the pruritus * Insufficient relief (WI-NRS ≥7/10 ) or poor tolerance (adverse effects) of accessible drug and non-drug therapies * Stable treatment (for treatment of the prurit) for at least 6 weeks * Affiliated or benefiting of a social security * Informed consent (personally dated and) signed by the participant or any representatives (impartial witness/trusted person) Exclusion Criteria: * Patients unable to consent. * Patients refusing to participate in research. * Patients under guardianship or conservatorship. * Personal history of psychotic disorders. * Severe hepatic impairment, defined as prothrombin level \<50% or with predictive biological impairment. * Moderate to severe renal impairment, with an estimated glomerular filtration rate ≤ 44 mL/min/1.73 m². * Severe cardiovascular or cerebrovascular disease, including history of myocardial infarction or stroke. * Pregnant or breastfeeding women. * Lack of understanding of questionnaires or inability to follow up. * Women of childbearing potential unwilling to use appropriate contraception. * Cannabinoid use outside the clinical trial * Use of cannabis or its derivatives less than one week before inclusion * History of hypersensitivity or allergy to any cannabinoid product. * Allergy to nuts.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pruritus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pruritus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHD Vendée

    La Roche-sur-Yon, France, 85925, France

  • CHRU de Tours

    Tours, France, 37044, France

  • CHU Angers

    Angers, France, 49000, France

  • CHU de Nantes

    Nantes, France, 44093, France

  • CHU de Poitiers

    Poitiers, France, 86000, France

  • Groupe Hospitalier La Rochelle

    La Rochelle, France, 17300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.